Supplementary Figure S4 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Abstract

Supp Figure S4. JAK1/2 inhibitor Ruxolitinib increases melanoma sensitivity to VSV-d51